Moderna Reaches $950 Million Settlement to Resolve Global Vaccine Patent Litigation

Biotechnology leader Moderna has announced a definitive settlement with Arbutus Biopharma Corporation and Genevant Sciences GmbH, effectively ending a long-standing global legal battle over mRNA delivery technology. The agreement clears the path for Moderna’s future vaccine portfolio by resolving all ongoing lawsuits worldwide.

Terms of the Agreement

Under the finalized deal, Moderna will provide a lump-sum payment of $950 million during the third quarter of 2026. A key feature of this settlement is the removal of future royalty requirements. This ensures that Moderna will not owe additional payments for the disputed lipid nanoparticle technology used in its current and future products.

The settlement covers a broad range of Moderna’s lipid nanoparticle-based products, including:

Current Vaccines: Spikevax (COVID-19) and mRESVIA (RSV).
Pipeline Candidates: Future infectious-disease vaccines such as mNEXSPIKE and mCOMBRIAX.

Financial Outlook and Contingencies

Moderna expects to record the $950 million charge in the first quarter of 2026. Despite this significant expenditure, the company maintains a robust financial position:

Liquidity: Moderna projects ending 2026 with $4.5 billion to $5.0 billion in cash and cash equivalents.
Pending Appeals: The company is still appealing a separate court decision regarding government-contractor immunity. While an unsuccessful appeal could theoretically lead to an additional payment of up to $1.3 billion, Moderna currently deems such a loss “not probable”.

A Shift Toward Future Growth

CEO Stéphane Bancel noted that resolving this “legacy matter” allows the company to move past pandemic-era uncertainties. Looking ahead to the remainder of 2026, Moderna is focused on several key milestones:

New Approvals: Anticipated greenlights for a flu plus COVID combination and standalone flu vaccines.
Clinical Trials: Expected results from high-stakes trials in cancer and rare diseases.
Financial Goals: A return to revenue growth in 2026, with a target to reach breakeven by 2028.